Triamcinolone Acetonide (Suprachoroidal Injectable Suspension)
Pronunciation: (zye-PEER).
- Generic name
- triamcinolone acetonide (suprachoroidal injectable suspension)
- Brand names
- Steranide, Xipere, Triacort, Tricort
- Drug class
- Eye, Ear, Nose & Throat
Availability and supply rules vary by country
Trade names by country: United States · Canada
Australia: · Full directory
What triamcinolone acetonide (suprachoroidal injectable suspension) is and how it works
Uses, formulations, monitoring, and supply rules can differ by patient, product, and country. Follow the exact local product information and professional advice.
Mechanism of action: how triamcinolone acetonide (suprachoroidal injectable suspension) works
Triamcinolone acetonide, the active ingredient in Xipere, is a synthetic corticosteroid with potent anti-inflammatory properties. When injected into the suprachoroidal space, it inhibits multiple inflammatory cytokines and mediators, reducing edema, leukocyte infiltration, and capillary permeability in the posterior segment of the eye. This targeted delivery maximizes local effect while minimizing systemic exposure. (1) (2)
What triamcinolone acetonide (suprachoroidal injectable suspension) is used for
Macular edema associated with uveitis
Macular edema associated with uveitis (2)
Diabetic macular edema
Diabetic macular edema (2)
Retinal vein occlusion
Retinal vein occlusion (2)
Before taking triamcinolone acetonide (suprachoroidal injectable suspension)
Do not take / not appropriate for
- active ocular or periocular infections (bacterial, viral, fungal), hypersensitivity to triamcinolone or formulation components, and uncontrolled glaucoma. (Contraindication) (2)
Tell your clinician about
(2)How to take triamcinolone acetonide (suprachoroidal injectable suspension)
- General Instructions: Xipere is administered as a suprachoroidal injection by a trained healthcare professional, typically in an outpatient ophthalmology clinic.. Adult Dosing: The recommended dose is 4 mg (0.1 mL) of triamcinolone acetonide suprachoroidal injectable suspension per affected eye. Repeat dosing may be considered based on clinical response and recurrence of symptoms.. Pediatric Dosing: Safety and efficacy in pediatric patients have not been established. Use in children is not routinely recommended.. Administration: Do not self-administer. The injection is given into the suprachoroidal space by an ophthalmologist or trained eye care provider under sterile conditions.. When To Stop: Treatment should be discontinued if there is evidence of severe side effects, lack of efficacy, or as directed by your healthcare provider.. Storage: Store the medication at 20°C to 25°C (68°F to 77°F). Protect from light and keep out of reach of children. Do not freeze.
- This page does not provide a dose calculator. Dosing must follow the prescriber, pharmacist, or product label.
Procedures and treatment changes
Tell the treating team before surgery, procedures, or any medicine change. Do not alter treatment without the responsible clinician. (2)
Missed dose
If you miss a scheduled injection, contact your healthcare provider as soon as possible to reschedule. Do not attempt to administer the medication yourself.
Overdose
Overdose is unlikely as Xipere is administered by a healthcare professional. However, if an overdose is suspected (e.g., multiple injections in error), seek immediate medical attention. Overdose may increase the risk of ocular hypertension, cataract formation, or infection. (2)
Side effects
Side effects and their urgency vary; report severe, persistent, or concerning symptoms to a healthcare professional.
Cataract
Incidence: Reported in the clinician-authored database; frequency not established
Increased intraocular pressure
Incidence: Reported in the clinician-authored database; frequency not established
Vitreous hemorrhage
Incidence: Reported in the clinician-authored database; frequency not established
Eye pain
Incidence: Reported in the clinician-authored database; frequency not established
Conjunctival hemorrhage
Incidence: Reported in the clinician-authored database; frequency not established
Blurred vision
Incidence: Reported in the clinician-authored database; frequency not established
Endophthalmitis
Incidence: Reported in the clinician-authored database; frequency not established
Serious warnings
May increase intraocular pressure — serious
Symptoms: May increase intraocular pressure; monitor for glaucoma. Risk of cataract formation with repeated use. May mask or worsen ocular infections. Not for use in active ocular infections. Should only be administered by trained professionals.
Action: Follow the urgency stated and seek prompt or emergency care when indicated. (2)
Contraindications recorded in the clinician database — serious
Symptoms: Contraindications recorded in the clinician database: Contraindications include active ocular or periocular infections (bacterial, viral, fungal), hypersensitivity to triamcinolone or formulation components, and uncontrolled glaucoma. Use with caution in patients with a history of ocular hypertension, cataracts, or herpes simplex infection. Monitor closely in immunosuppressed patients.
Action: Follow the urgency stated and seek prompt or emergency care when indicated. (2)
Interactions
| Medicine or test | Effect | Action |
|---|---|---|
| Recorded interactions | Xipere may interact with other corticosteroid-containing medications, immunosuppressive agents, and drugs that affect intraocular pressure. Inform your doctor of all medications, including over-the-counter and herbal products. Use caution with other ophthalmic agents, and avoid concurrent use of live vaccines. | (1) |
Pregnancy, breastfeeding, kidney/liver function, age
Pregnancy
Requires a primary-source research pass before this section can be completed. (2)
Breastfeeding
Requires a primary-source research pass before this section can be completed. (2)
Children
Frequency: Not applicable.. Weight Based: Not recommended for pediatric use.. Max Daily Dose: Not applicable.. Max Single Dose: Not applicable.. Age Restrictions: Safety not established in children. (2)
Renal_impairment
Requires a primary-source research pass before this section can be completed. (2)
Hepatic_impairment
Requires a primary-source research pass before this section can be completed. (2)
Monitoring
(2)Storage
Requires a primary-source research pass before this section can be completed.
Professional information
Clinician-facing context only. This section does not replace current product labeling.
General
Indication: Macular edema associated with uveitis
Dose summary: 4 mg (0.1 mL) administered as a suprachoroidal injection.
Renal context: FDA label (Xipere): the Use in Specific Populations section covers pregnancy, lactation, pediatric, and geriatric use only — there is no dedicated renal-impairment subsection or dose adjustment. Xipere is a single 4 mg suprachoroidal injection given by an ophthalmologist directly into the eye, with limited systemic corticosteroid exposure expected compared with oral or injectable systemic steroids, which is the likely reason no renal dosing table exists; renal status should still be part of the prescriber's overall assessment. (1) (2)
Hepatic guidance
FDA label (Xipere): no dedicated hepatic-impairment subsection or dose adjustment is given, consistent with the limited systemic absorption expected from a single suprachoroidal ocular injection. Triamcinolone acetonide (the active steroid) is hepatically metabolized when it does reach the systemic circulation, so significant hepatic impairment could theoretically affect systemic clearance in the small fraction absorbed, but the label does not provide a numeric adjustment; hepatic status should still be part of the prescriber's overall assessment.
Frequently asked questions
What is Xipere used for?
Xipere is used to treat macular edema associated with uveitis, an inflammatory condition affecting the back of the eye. It helps reduce swelling and improve vision.
How is Xipere administered?
Xipere is given as a suprachoroidal injection by an eye care professional in a clinical setting. It is not for self-administration.
What are the most common side effects?
Common side effects include eye pain, blurred vision, increased intraocular pressure, and mild redness or discomfort at the injection site.
Can Xipere cause glaucoma or cataracts?
Yes, repeated use of corticosteroids like Xipere can increase the risk of developing glaucoma or cataracts. Regular eye exams are important.
Is Xipere safe during pregnancy or breastfeeding?
The safety of Xipere in pregnancy or breastfeeding is not well established. Discuss risks and benefits with your doctor before use.
What should I do if I miss a dose?
Contact your healthcare provider to reschedule the missed injection. Do not attempt to administer the medication yourself.
Can I use other eye drops with Xipere?
Only use other eye medications if approved by your doctor, as some drugs may interact with Xipere or affect its efficacy.
What happens if I take too much Xipere?
As Xipere is administered by a healthcare professional, overdose is unlikely. However, if you experience any unusual or severe eye pain, vision changes, or other concerning symptoms after your injection, it is crucial to seek immediate medical attention. Your doctor will monitor for potential complications such as elevated intraocular pressure or other adverse reactions.
Can I drink alcohol while taking Xipere?
There are no known direct interactions between alcohol consumption and Xipere (triamcinolone acetonide) as an ophthalmic corticosteroid. However, it is always advisable to discuss alcohol intake with your healthcare provider, especially if you have underlying medical conditions or are taking other medications. Excessive alcohol can sometimes exacerbate certain health issues or interact with other systemic treatments you might be receiving.
Is Xipere safe during pregnancy?
The safety of Xipere during pregnancy has not been definitively established. It is categorized as 'Consult doctor' regarding pregnancy. If you are pregnant, planning to become pregnant, or breastfeeding, it is essential to inform your healthcare provider before receiving Xipere. They will assess the potential risks and benefits to determine the most appropriate course of treatment for your specific situation.
What is the mechanism of action of triamcinolone acetonide (suprachoroidal injectable suspension)?
Triamcinolone acetonide, the active ingredient in Xipere, is a synthetic corticosteroid with potent anti-inflammatory properties. When injected into the suprachoroidal space, it inhibits multiple inflammatory cytokines and mediators, reducing edema, leukocyte infiltration, and capillary permeability in the posterior segment of the eye. This targeted delivery maximizes local effect while minimizing systemic exposure. (1) (2)
What is the generic name of Triamcinolone Acetonide (Suprachoroidal Injectable Suspension)?
The generic name is triamcinolone acetonide (suprachoroidal injectable suspension). It is sold under brand names including Steranide, Xipere, Triacort, Tricort.
What class of drug is triamcinolone acetonide (suprachoroidal injectable suspension)?
Triamcinolone Acetonide (Suprachoroidal Injectable Suspension) is classed as: Eye, Ear, Nose & Throat.
References
- Clinician-authored medicine record for Xipere (MedGuideGlobal medicines database) · · accessed 2026-08-07 · source 1
- XIPERE (triamcinolone acetonide) injectable suspension, for suprachoroidal use — FDA prescribing information, DailyMed · · accessed 2026-08-07 · source 2
- TRIADERMEX (TRIAMCINOLONE ACETONIDE) KIT [FLORRAX PHARMACEUTICAL] — US prescribing information (DailyMed SPL)U.S. National Library of Medicine (DailyMed) · US · accessed 2026-08-14 · source 3
- Nystatin and Triamcinolone — patient drug information (MedlinePlus)U.S. National Library of Medicine (MedlinePlus) · US · accessed 2026-08-14 · source 4
- triamcinolone acetonide — RxNorm normalized drug concept (RXCUI 10761)U.S. National Library of Medicine (RxNorm) · US · accessed 2026-08-14 · source 5
Brand names by country
Single-ingredient triamcinolone acetonide (suprachoroidal injectable suspension) names are shown separately by country. Product availability, strengths, and supply rules can change; combination products are not included here.
Priority countries
United States
- KENALOG-1040 mg/mL, 80 mg/mL, 10 mg/mL · asclemed usa, inc.
- TRIESENCE40 mg/mL · novartis pharmaceuticals corporation
- NASACORT55 ug · a-s medication solutions
- TRIDERM.25 mg/g, 5 mg/g, 1 mg/g · crown laboratories
- Triloan SUIK40 mg/mL · asclemed usa, inc.
- Xipere40 mg/mL · bausch & lomb incorporated
- Triloan II SUIK40 mg/mL · asclemed usa, inc.
- Oralone1 mg/g · sun pharmaceutical industries, inc.
- KOURZEQ1 mg/g · midamerica pharmaceuticals
Canada
- KENALOG-10
- ARISTOCORT R
- TRIADERM CRM
- ORACORT DENTAL PASTE
- NASACORT AQ
- ARISTOCORT C
- TRIESENCE
- NASACORT ALLERGY
- TRIADERM ONT
- APO-TRIAMCINOLONE AQ